TABLE 1.

Clinical, histological, and molecular characteristics of patients with CNS tumors with genomic rearrangements or fusions.

ID	Age at Diagnosis (years)	Sex	Tumor Location	Histologic Diagnosis	WHO Grade	Genetic Alteration	Method of Testing	Therapy	Follow-up (months)	Follow-up Status
1	0.4	F	Brainstem, thalamus, chiasm	Diffuse astrocytoma	II	FGFR1 TKD duplication	Archer	Biopsy → Carboplatin/ Etoposide	10.5	Progression
								Vinblastine/ Avastin	4.5	Death
2	3	M	Bilateral thalamus	Pediatric type oligodendroglioma	II	FGFR1 TKD duplication	Archer	Biopsy→ Obs	1.5	Progression
			Frontal horn	PA	I			Carboplatin/ Vinblastine + RT	25	Death
3	2	F	Hypo-thalamus	PMA	I	FGFR1 TKD duplication	Archer	Biopsy→ Carboplatin/ VCR /Gleevec/TMZ	4	Progression
								Re-resection	4	Death
4	9	M	Temporo-parietal	Extraventricular neurocytoma	II	FGFR1-TACC1	Archer	STR → GTR + RT	8	Alive
5	1.8	M	Medullary/ Cervical spine	PA/PMA		FGFR1-TACC1	Archer	STR→ Obs	2	Progression
								RT + Trametinib	19	Alive, on therapy
6	16	F	Tectal plate	PA	I	FGFR-TACC1	Archer	Biopsy→Obs	15	Alive
7*	6	F	Peri-insular	Ganglioglioma	I	FGFR2-KIAA1598 fusion	Archer	New patient	N/A	N/A
8^	5	M	Thalamus	PA	II	MYB-QKI	Archer	Biopsy→ Carboplatin/ VCR	3	Progression
								STR, RT→ MEK inhibitor → multi-kinase inhibitor + everolimus	102	Alive, progressive disease
9^	2	M	Frontal	PMA (NF1-associated)	II	MYB-QKI	Archer	GTR	15	Progression
			Frontal, Cervical spine					GTR→ Carboplatin → Trametinib	42	Alive, progressive disease
10*	8	F	Cauda equina	EPN w/ myxo-papillary features	II	PPP1CB-ALK	Archer	GTR	99	Alive
11	3	F	Frontal	Epithelioid GBM	IV	ETV6-NTRK3	Archer	STR + Carboplatin/ Etoposide	2	Progression
								RT + NTRK inhibitor	11	Alive, on therapy
12	10	F	Pons	DIPG	IV	ZKSCAN1-NTRK3	Archer	Biopsy → RT + Avastin	3	Death
13	6	M	Thalamus	PA	I	GOPC-ROS1	Archer	GTR	13	Alive
14	7	M	Cerebellum	PA	I	SRGAP3-RAF1	Archer	GTR	26	Alive
15	18	F	Brainstem	Infiltrating glioma with equivocal ganglioglioma component	I-II	N/A	Archer	Biopsy→ RT + Avastin	59	Progression
			Cerebellum	Anaplastic infiltrating glioma		PTPRZ1-MET		Re-Biopsy→ TMZ + RT	3	Alive, on therapy
16*	19	F	Fronto-parietal	Anaplastic ganglioglioma	III	CIC-LEUTX	Research RNA-Seq	GTR	10	Progression
								RT + TMZ → STR + RT (CSI) + Carboplatin → Cytoxan/Doxo/Ifos/Etoposide	56	Alive, progressive disease
17*	12	F	Intra-ventricular	Metastatic anaplastic astrocytoma with epithelioid GBM features	III-IV	CIC-LEUTX	Foundation One	GTR + RT/TMZ	3	Alive, on therapy
18*	5	F	Frontal	Astroblastoma		MN1-BEND2	Research RNA-Seq	GTR	85	Alive
19#	3	M	Temporal	EPN	II	MN1-CXXC5	Research RNA-Seq	GTR	8	Progression
20	5	M	Parietal	Anaplastic EPN	III	C11orf95-RELA	Archer	GTR + proton RT (elsewhere)	13	Progression
				Metastatic anaplastic EPN				PD1 inhibitor + debulking of metastases x 2	3	Alive, on therapy
21	5	F	Temporal	Metastatic anaplastic EPN	III	C11orf95-RELA	Archer	GTR + RT (elsewhere)	10	Progression
								PD1 inhibitor	5	Death
22	11	M	Parietal	Anaplastic EPN	III	C11orf95-RELA	St. Jude	NTR (elsewhere), re-resection +focal RT	2	Progression
								Re-resection	1	Alive, on therapy
23	3	F	Thalamus	PA	I-II	ETV-ITPR2	Archer	STR + Carboplatin/ Vinblastine	16	Alive
24#	0.5	M	4th ventricle	Anaplastic EPN	III	BRAF-KIAA1549	Archer	STR + Carboplatin/ Etoposide → GTR + RT	77	Alive

^*indicates patients with a previously unreported or extremely rare fusion for a diagnosis.

^#indicates patients for whom histological and molecular findings were discordant and molecular findings led to a change in diagnosis.

^{^}indicates patients for whom a fusion result prompted diagnosis refinement.

TKD=tyrosine kinase domain, PA=pilocytic astrocytoma, STR=subtotal resection, GTR=gross total resection, PMA=pilomyxoid astrocytoma, VCR=vincristine, TMZ=temozolomide, Obs=observation, RT=radiation therapy, NF1=neurofibromatosis type 1, EPN=ependymoma, GBM=glioblastoma, DIPG=diffuse intrinsic pontine glioma, NTR=near-total resection, NTRK=neurotrophic receptor tyrosine kinase, Doxo=doxorubicin, Ifos=ifosfamide, PNET=primitive neuroectodermal tumor, autoSCT=autologous stem cell transplant, PD1=programmed cell death protein 1, Archer= Archer fusion panel conducted at CLIA-certified Colorado Molecular Correlates Laboratory (CMOCO)